Cadherin-11 contributes to liver fibrosis induced by carbon tetrachloride
Liver fibrosis is characterized by the excessive deposition of extracellular matrix (ECM) leading to impaired function and cirrhosis. Previous reports support a role for cadherin-11 (CDH11) in regulating the development of dermal and pulmonary fibrosis. In the current report, the extent to which CDH...
Saved in:
Published in | PloS one Vol. 14; no. 7; p. e0218971 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
United States
Public Library of Science
03.07.2019
Public Library of Science (PLoS) |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Liver fibrosis is characterized by the excessive deposition of extracellular matrix (ECM) leading to impaired function and cirrhosis. Previous reports support a role for cadherin-11 (CDH11) in regulating the development of dermal and pulmonary fibrosis. In the current report, the extent to which CDH11 modulates the development of liver fibrosis induced by carbon tetrachloride (CCL4) was assessed.
Wild type (WT) and CDH11 deficient (CDH11-/-) mice were treated with CCl4 or vehicle control for 8 weeks to induce liver fibrosis. Liver fibrosis was assessed by histology, collagen content, and RTPCR of fibrotic mediators.
Livers from WT mice treated with CCl4 had increased levels of CDH11 which localized to injured hepatocytes, hepatic stellate cells, and macrophages. Interestingly, CDH11-/- mice had decreased histological evidence of liver fibrosis, collagen deposition, α-smooth muscle actin (α-SMA) accumulation, and mRNA levels of fibrotic mediators such as Col1-α1, Snail, TGF-β and IL-6.
These data demonstrate that CDH11 is increased during liver fibrosis, is an important regulator of liver fibrosis induced by CCL4 and suggest that CDH11 may be a potential therapeutic target for liver fibrosis. |
---|---|
Bibliography: | Competing Interests: Dr. Agarwal holds the patent for targeting cadherin-11 in fibrotic disease entitled “Detection and treatment of non-dermal fibrosis” (US8877188B2). The patent dose not alter our adherence to the PLOS ONE policies regarding sharing data and materials. All the experiments were funded, designed, performed and analyzed completely independent of pharmaceutical companies developing therapeutics to target cadherin-11 (e.g. Roche). SANDEEP. This does not alter our adherence to PLOS ONE policies on sharing data and materials. |
ISSN: | 1932-6203 1932-6203 |
DOI: | 10.1371/journal.pone.0218971 |